Meeder Advisory Services Inc. Has $1.60 Million Holdings in Boston Scientific Co. (NYSE:BSX)

Meeder Advisory Services Inc. boosted its position in shares of Boston Scientific Co. (NYSE:BSX) by 3.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 23,332 shares of the medical equipment provider’s stock after buying an additional 745 shares during the quarter. Meeder Advisory Services Inc.’s holdings in Boston Scientific were worth $1,598,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Meeder Asset Management Inc. lifted its holdings in Boston Scientific by 7.9% during the 1st quarter. Meeder Asset Management Inc. now owns 4,102 shares of the medical equipment provider’s stock worth $281,000 after buying an additional 299 shares in the last quarter. NorthRock Partners LLC lifted its holdings in Boston Scientific by 6.8% during the 1st quarter. NorthRock Partners LLC now owns 9,155 shares of the medical equipment provider’s stock worth $627,000 after buying an additional 585 shares in the last quarter. Fiduciary Family Office LLC lifted its holdings in Boston Scientific by 42.9% during the 1st quarter. Fiduciary Family Office LLC now owns 14,512 shares of the medical equipment provider’s stock worth $994,000 after buying an additional 4,359 shares in the last quarter. Concurrent Investment Advisors LLC lifted its holdings in Boston Scientific by 14.7% during the 1st quarter. Concurrent Investment Advisors LLC now owns 8,301 shares of the medical equipment provider’s stock worth $569,000 after buying an additional 1,066 shares in the last quarter. Finally, Atomi Financial Group Inc. lifted its holdings in Boston Scientific by 23.9% during the 1st quarter. Atomi Financial Group Inc. now owns 6,030 shares of the medical equipment provider’s stock worth $413,000 after buying an additional 1,163 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Boston Scientific stock traded up $0.33 during midday trading on Monday, reaching $78.02. 6,477,576 shares of the company’s stock were exchanged, compared to its average volume of 6,163,819. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $78.98. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66. The firm has a market cap of $114.46 billion, a price-to-earnings ratio of 65.56, a P/E/G ratio of 2.67 and a beta of 0.78. The stock’s 50-day simple moving average is $75.91 and its 200 day simple moving average is $69.29.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.51 by $0.05. Boston Scientific had a return on equity of 16.39% and a net margin of 12.06%. The business had revenue of $3.86 billion during the quarter, compared to analysts’ expectations of $3.68 billion. On average, analysts expect that Boston Scientific Co. will post 2.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $77.30, for a total transaction of $539,785.90. Following the completion of the transaction, the executive vice president now owns 42,908 shares in the company, valued at $3,316,788.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $77.30, for a total transaction of $539,785.90. Following the completion of the sale, the executive vice president now owns 42,908 shares in the company, valued at $3,316,788.40. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 14,011 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $75.34, for a total value of $1,055,588.74. Following the sale, the executive vice president now owns 20,197 shares of the company’s stock, valued at approximately $1,521,641.98. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 72,259 shares of company stock worth $5,344,014. Company insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on BSX. Royal Bank of Canada increased their price target on Boston Scientific from $78.00 to $82.00 and gave the company an “outperform” rating in a research note on Thursday, April 25th. Argus increased their price target on Boston Scientific from $80.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, May 28th. UBS Group increased their price target on Boston Scientific from $74.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. JPMorgan Chase & Co. increased their price target on Boston Scientific from $72.00 to $82.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th. Finally, Morgan Stanley increased their price target on Boston Scientific from $79.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday. Two investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $80.71.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.